scholarly journals Cerebrospinal fluid protein biomarkers for Alzheimer’s disease

NeuroRx ◽  
2004 ◽  
Vol 1 (2) ◽  
pp. 213-225 ◽  
Author(s):  
Kaj Blennow
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Protein Biomarkers ◽  
Cerebrospinal Fluid Protein

scholarly journals Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer’s disease

2020 ◽  
Vol 6 (43) ◽  
pp. eaaz9360 ◽  
Author(s):  
Lenora Higginbotham ◽  
Lingyan Ping ◽  
Eric B. Dammer ◽  
Duc M. Duong ◽  
Maotian Zhou ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Wide Spectrum ◽  
Csf Biomarkers ◽  
Protein Biomarkers ◽  
Cerebrospinal Fluid Biomarkers ◽  
Brain Proteome ◽  
The Brain ◽  
Underlying Pathophysiology

Alzheimer’s disease (AD) lacks protein biomarkers reflective of its diverse underlying pathophysiology, hindering diagnostic and therapeutic advancements. Here, we used integrative proteomics to identify cerebrospinal fluid (CSF) biomarkers representing a wide spectrum of AD pathophysiology. Multiplex mass spectrometry identified ~3500 and ~12,000 proteins in AD CSF and brain, respectively. Network analysis of the brain proteome resolved 44 biologically diverse modules, 15 of which overlapped with the CSF proteome. CSF AD markers in these overlapping modules were collapsed into five protein panels representing distinct pathophysiological processes. Synaptic and metabolic panels were decreased in AD brain but increased in CSF, while glial-enriched myelination and immunity panels were increased in brain and CSF. The consistency and disease specificity of panel changes were confirmed in >500 additional CSF samples. These panels also identified biological subpopulations within asymptomatic AD. Overall, these results are a promising step toward a network-based biomarker tool for AD clinical applications.

scholarly journals Characterization and clinical use of inflammatory cerebrospinal fluid protein markers in Alzheimer’s disease

2018 ◽  
Vol 10 (1) ◽  
Author(s):  
Frederic Brosseron ◽  
Andreas Traschütz ◽  
Catherine N. Widmann ◽  
Markus P. Kummer ◽  
Pawel Tacik ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Clinical Use ◽  
Protein Markers ◽  
Cerebrospinal Fluid Protein

Cerebrospinal fluid protein tau levels in the differential diagnosis of Alzheimer's disease

2000 ◽  
Vol 21 ◽  
pp. 28-29
Author(s):  
Peter Schoenknecht ◽  
Johannes Schroeder ◽  
Johannes Pantel ◽  
Egon Werle ◽  
Tobias Hartmann ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Differential Diagnosis ◽  
Protein Tau ◽  
Cerebrospinal Fluid Protein

Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease

2003 ◽  
Vol 118 (1-2) ◽  
pp. 140-146 ◽  
Author(s):  
Maja Puchades ◽  
Sara Folkesson Hansson ◽  
Carol L Nilsson ◽  
Niels Andreasen ◽  
Kaj Blennow ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Protein Markers ◽  
Cerebrospinal Fluid Protein

Idiopathic normal pressure hydrocephalus and Alzheimer's disease in clinical practice: comorbidity and differentiation

2020 ◽  
pp. 36-43
Author(s):  
V. Yu. Lobzin ◽  
M. R.o. Alizade ◽  
A. V. Lapina ◽  
S. V. Lobzin ◽  
K. A. Kolmakova ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Cognitive Impairment ◽  
Normal Pressure Hydrocephalus ◽  
Normal Pressure ◽  
Brain Parenchyma ◽  
Idiopathic Normal Pressure Hydrocephalus ◽  
Protein Biomarkers ◽  
Brain Functions

The idiopathic normal pressure hydrocephalus (Hakim – Adams syndrome) is characterized by the expansion of cerebrospinal cavities, which is clinically manifested by triad symptoms: cognitive impairment, impaired gait and urination. In this research the severity and modality of cognitive impairment, the pattern of gait changes and the levels of protein biomarkers of amyloidosis and neurodegeneration and neuroimaging changes was evaluated for idiopathic normal pressure hydrocephalus, Alzheimer's disease and their combination. It has been established that for patients with idiopathic normal pressure hydrocephalus the most characteristic is the dysregulatory type of disorders of higher brain functions, while for patients with a combination of Alzheimer's disease and idiopathic normal pressure hydrocephalus, mnemonic disorders are also detected. The specific changes of cerebrospinal fluid in patients with idiopathic normal pressure hydrocephalus are higher levels of amyloid beta, a decrease concentration of tau and phosphorylated tau-protein compared to patients with Alzheimer's disease. In the case of a combination of diseases (comorbidity), it was characterized by intermediate results by cerebrospinal fluid biomarkers. We also revealed patterns of transformation of moderate cognitive impairment into dementia (according to the ratio of tau/Aβ‑42 and ftau /Aβ‑42). The value of evaluating the results of magnetic resonance imaging using special techniques that evaluate both the expansion of the ventricular system and atrophy of the brain parenchyma. Comorbid patients are characterized by a combination of these processes based on the results of neuroimaging. That is why it is necessary to use complex visually analog neuroimaging scales for differential diagnosis and establishing diagnosis. Also, in the course of this work, an algorithm is proposed for mandatory clinical-neuropsychological and laboratory-instrumental examination of patients with cognitive impairment in idiopathic normal pressure hydrocephalus, Alzheimer's disease and their combination.

scholarly journals Cerebrospinal Fluid Biomarkers in Familial Forms of Alzheimer's Disease and Frontotemporal Dementia

2015 ◽  
Vol 40 (1-2) ◽  
pp. 54-62 ◽  
Author(s):  
Nina Rostgaard ◽  
Gunhild Waldemar ◽  
Jørgen Erik Nielsen ◽  
Anja Hviid Simonsen
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Frontotemporal Dementia ◽  
Core Protein ◽  
Tau Pathology ◽  
Protein Biomarkers ◽  
Cerebrospinal Fluid Biomarkers ◽  
Best Medical Treatment ◽  
New Biomarkers

As dementia is a fast-growing health care problem, it is becoming an increasingly urgent need to provide an early diagnosis in order to offer patients the best medical treatment and care. Validated biomarkers which reflect the pathology and disease progression are essential for diagnosis and are important when developing new therapies. Today, the core protein biomarkers amyloid-β42, total tau and phosphorylated tau in the cerebrospinal fluid (CSF) are used to diagnose Alzheimer's disease (AD), because these biomarkers have shown to reflect the underlying amyloid and tau pathology. However, the biomarkers have proved insufficient predictors of dementias with a different pathology, e.g. frontotemporal dementia (FTD); furthermore, the biomarkers are not useful for early AD diagnosis. Familial dementias with a known disease-causing mutation can be extremely valuable to study; yet the biomarker profiles in patients with familial dementias are not clear. This review summarizes CSF biomarker findings from studies on symptomatic and presymptomatic individuals carrying a mutation in one of the genes known to cause early-onset familial AD or FTD. In conclusion, the biomarker profile of inherited AD is quite similar between carriers of different mutations as well as similar to the profile found in sporadic AD, whereas familial FTD does not seem to have a clear biomarker profile. Hence, new biomarkers are needed for FTD.

Sign in / Sign up

Export Citation Format

Share Document